Bibliographic information
Recommendation
Treatment is recommended for all adults with chronic hepatitis B (CHB) (including pregnant women and girls and women of reproductive age) with: 1. Evidence of significant fibrosis (≥F2b) based on an APRI score of >0.5 or transient elastography value of >7 kPa or evidence of cirrhosis (F4) based on clinical criteria (or an APRI score of >1 or transient elastography value of >12.5 kPab), regardless of HBV DNA or ALT levels.
Recommended in favor
Strong
Certainty of evidence
Moderate
Notes and Remarks
Chronic hepatitis B (CHB): Defined as the presence of HBsAg on at least one occasion, and for adolescents and children, persistence of HBsAg for six months or more. Clinical features of decompensated cirrhosis: portal hypertension (ascites, variceal haemorrhage and hepatic encephalopathy), coagulopathy or liver insufficiency (jaundice). Other clinical features of advanced liver disease and cirrhosis may include: hepatomegaly, splenomegaly, pruritus, fatigue, arthralgia, palmar erythema and oedema